Tenet Healthcare Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a THC research report →
Range $265 – $308
Price Chart
About the company
Tenet Healthcare Corporation operates as a broad-ranging provider of health solutions. The company organizes its operations across three main divisions: Hospital Operations and Other, Ambulatory Care, and Conifer. Within its network of acute care facilities, Tenet delivers a full spectrum of essential services.
- CEO
- Saumya Sutaria
- IPO
- 1980
- Employees
- 88,500
- HQ
- Dallas, TX, US
AI snapshot
Six angles, distilled from the data.
The stock remains in a strong multi-month uptrend, trading above its 200-day moving average and not far from its 52-week high. That keeps the primary regime constructive, though the recent pullback from the upper end of the range suggests momentum is cooling rather than breaking.
Street sentiment stays constructive, with a Buy consensus and a target cluster centered in the high-200s to low-300s. Recent action has been mostly target maintenance and modest raises, including Mizuho at $305 and Guggenheim at $306, which keeps the setup favorable but not euphoric.
Earnings execution has been excellent, with 8 straight EPS beats and the last four surprises ranging from 15.5% to 50.0%. The next watchpoint is whether management can keep beating while consensus EPS for next year sits below the current TTM run rate, signaling tougher comparisons ahead.
Insider activity leans negative, with 13 sells and no open-market buys. The heaviest selling came from the CEO and several directors in August and September, while the few gifts are noise rather than conviction signals; shareholders should watch whether selling moderates after the recent run.
Profitability is strong, led by a 19.12% operating margin and 41.7% ROE, with revenue up 6.5% year over year. Cash generation is also solid at $4.55 billion of free cash flow, but leverage remains meaningful with $13.17 billion of debt against $2.883 billion of cash.
Tenet stands out for stronger profitability and cash conversion than many hospital operators, supported by a 42.5% gross margin and double-digit net margin. Valuation is not cheap, but the market is still pricing it below the $289 consensus target and near the lower end of the $265 to $308 target range.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $20.95B
- P/E
- 7.59
- Fwd P/E
- 11.64
- PEG
- 0.06
- P/S
- 0.92
- P/B
- 3.88
- EV/EBITDA
- 5.33
- Div Yield
- 0.00%
- Gross Margin
- 29.38%
- Op Margin
- 19.85%
- Net Margin
- 12.71%
- ROE
- 60.60%
- ROIC
- 13.80%
Latest fiscal year · YoY change
- Revenue
- $21.31B+3.1%
- Gross Profit
- $17.53B+113.5%
- Op Income
- $3.44B
- Net Income
- $1.41B-56.0%
- EPS
- $15.61-52.7%
- OCF Growth
- +72.9%
- FCF Growth
- +126.7%
- 52W High
- $301.44
- 52W Low
- $157.58
- 50D MA
- $268.89
- 200D MA
- $226.57
- Beta
- 1.20
- RSI (14)
- 41
- Avg Volume
- 806.27K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Tenet reported a strong third quarter with revenue and EBITDA ahead of expectations, raised full-year 2026 guidance, and said it still expects adjusted EBITDA growth in 2027 excluding Conifer transition items.· October 29, 2026
- Q3 net operating revenues were $5.6 billion, consolidated adjusted EBITDA was $1.355 billion, and adjusted diluted EPS increased 80% to $6.40.
- Adjusted EBITDA margin was 21.8%; management said core performance remained strong even after adjusting for one-time Conifer transition benefits.
- USPI adjusted EBITDA rose 9% to $537 million, with same-facility revenues up 4.5% and net revenue per case up 6.1%.
- Hospital same-facility adjusted admissions grew 3.2%, while exchange admissions and revenues declined 18% year over year.
- The company raised 2026 adjusted EBITDA guidance to $5.05 billion to $5.2 billion and increased adjusted free cash flow after NCI guidance to $1.925 billion to $2.155 billion.
Tenet reported third-quarter 2026 net operating revenues of $5.6 billion and consolidated adjusted EBITDA of $1.355 billion. Adjusted diluted EPS increased 80% year over year to $6.40, and adjusted EBITDA margin was 21.8%. USPI adjusted EBITDA grew 9.1% to $537 million, with same-facility systemwide revenues up 4.5% and net revenue per case up 6.1%; same-facility case volumes were down 1.5%. In the hospital segment, same-hospital adjusted admissions rose 3.2%, revenue per adjusted admission increased 0.2%, and exchange admissions and revenues declined 18% from the prior year. The company recognized $32 million of out-of-period supplemental Medicaid revenues in the quarter, versus $38 million in Q3 2025, and $147 million of net benefit tied to Conifer transition activities, including $97 million of revenue timing and $50 million of EBITDA from earlier-than-expected expense reductions. For 2026, Tenet now expects net operating revenues of $22.05 billion to $22.45 billion, adjusted EBITDA of $5.05 billion to $5.2 billion, and adjusted free cash flow after NCI of $1.925 billion to $2.155 billion; excluding $150 million of tax payments tied to the Conifer transaction, adjusted free cash flow after NCI would be $2.2 billion at the midpoint. Management said it expects overall adjusted EBITDA growth in 2027 excluding the $450 million of 2026 Conifer transition items, while noting further planning details will come in Q4.
Saumya Sutaria said Tenet’s core business continues to grow despite payer mix shifts, exchange enrollment declines, and a still-not-robust surgical backdrop. He emphasized that the company’s high-acuity strategy, diversified mix, and technology-enabled operating model are supporting margin strength, cash flow, and differentiated growth in both USPI and hospitals. He also highlighted confidence in 2027, saying the company expects EBITDA growth excluding Conifer transition items and sees healthy patient demand and stable conditions under current regulatory assumptions.
Sun K. Park focused on margin execution, operating expense discipline, and the cash-flow profile of the business. He cited $5.6 billion of revenue, $1.355 billion of adjusted EBITDA, 39.2% USPI adjusted EBITDA margin, $1.1 billion of adjusted free cash flow in the quarter, and $2.5 billion year to date. He also noted $2.67 billion of cash on hand, no borrowings under the line of credit, $255 million of share repurchases in the quarter, and $1.615 billion of repurchases year to date; leverage was 2.11x EBITDA, or 2.58x EBITDA less NCI. On capital structure, he said the company issued $2 billion of 2034 notes and retired $2 billion of 2027 and 2028 notes, leaving no significant debt maturities until 2028.
Analysts pressed management on commercial pricing sustainability, Medicaid supplemental payments and possible HR1 exposure, exchange-driven volume softness, surgical demand trends, and the durability of hospital margin expansion. Management said commercial renewals remain in the 3% to 5% range and that the company is over 90% contracted for next year, while declining to break out what portion of supplemental Medicaid payments could be affected by HR1; it disclosed $356 million of total supplemental Medicaid payments for the quarter. On surgery, management said the environment is not “gangbusters,” but Tenet is performing well relative to the industry thanks to its high-acuity strategy, USPI share capture, and lower-cost site-of-care migration. On exchanges, management described Q3 as a stabilization quarter after Q2 acceleration, with exchange admissions and revenues down 18% year over year.
The call showed strong operating momentum, with revenue, EBITDA, EPS, cash flow, and segment growth all coming in strong enough to justify another guidance increase. Management sounded confident that its mix of high-acuity hospitals, USPI expansion, and cost controls can keep driving earnings even as exchange volumes fall and the surgical market remains mixed. The company also has substantial shareholder return capacity, having already repurchased $1.615 billion of stock year to date and citing strong liquidity and no near-term debt pressure.
The main risks discussed were payer-mix pressure, exchange enrollment declines, and uncertainty around Medicaid/work requirement policy under HR1. Management also acknowledged that the surgery environment is not especially strong and that some of the year’s EBITDA upside came from one-time Conifer transition items and timing shifts that will not recur. Analysts also raised concerns about uncompensated care trends and whether the current margin trajectory can be sustained as the business laps these benefits.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.1%
- Shares Outstanding
- 79.59M
- Float Shares
- 78.83M
of shares held by institutions
720 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for THC, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Jonathan JacksonHouse · IL01 | Sell | Apr 20, 26 | Filing → |
| Jonathan JacksonHouse · IL01 | Sell | Apr 15, 26 | Filing → |
| Jonathan JacksonHouse · IL01 | Sell | Feb 11, 26 | Filing → |
| Jonathan JacksonHouse · IL01 | Buy | Dec 10, 25 | Filing → |
| Jonathan JacksonHouse · IL01 | Buy | Sep 3, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Aug 4, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 11, 25 | Filing → |
| John JamesHouse · MI10 | Sell | Sep 4, 24 | Filing → |
| John JamesHouse · MI10 | Buy | Nov 10, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 8.86M | ▼ 153.57K |
| Blackrock, Inc. | 8.36M | ▼ 381.51K |
| Price T Rowe Associates Inc | 7.96M | ▲ 438.71K |
| Boston Partners | 4.06M | ▼ 368.70K |
| Vanguard Portfolio Management LLC | 4.00M | ▼ 235.26K |
| Fmr LLC | 3.92M | ▼ 70.29K |
| Vanguard Capital Management LLC | 3.62M | ▼ 272.42K |
| State Street Corp | 2.65M | ▼ 100.67K |
| Glenview Capital Management, LLC | 2.24M | ▲ 710.81K |
| Citadel Advisors LLC | 1.77M | ▲ 1.35M |
| Ameriprise Financial Inc | 1.66M | ▲ 171.95K |
| Arrowstreet Capital, Limited Partnership | 1.66M | ▼ 53.16K |
Held by 768 ETFs
Biggest fund positions in THC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | MARK RICHARD J | other | 687 |
| Nov 11, 26 | Blunt Roy | sell | 1,000 |
| Sep 14, 26 | KERREY J ROBERT | sell | 5,483 |
| Sep 14, 26 | KERREY J ROBERT | sell | 4,025 |
| Sep 14, 26 | KERREY J ROBERT | sell | 2,502 |
| Sep 10, 26 | MARK RICHARD J | sell | 10,000 |
| Sep 2, 26 | West Nadja | sell | 1,152 |
| Aug 31, 26 | Foo Lisa Y | sell | 24,000 |
| Aug 28, 26 | HANEY CECIL D | other | 150 |
| Aug 24, 26 | HANEY CECIL D | sell | 1,300 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our THC coverage
Recent articles, reports, and earnings notes.

Tenet Healthcare (THC): Ambulatory Growth Drives Upside
Tenet Healthcare delivered a strong Q2 with rising hospital margins, accelerating ambulatory EBITDA, and higher 2026 guidance. The stock still screens as a Buy despite debt and payer-mix risk.

Tenet Healthcare Corporation (THC) jumps on deep earnings beat
Tenet Healthcare Corporation (THC) jumps after a sharp Q2 beat, but the real story is in the margins, segment mix, and raised outlook. This deep-dive breaks down USPI strength, hospital EBITDA gains, exchange revenue pressure, and why management’s higher 2026 guidance matters.

Tenet Healthcare Corporation (THC) spikes on earnings beats
Tenet Healthcare Corporation (THC) spikes after reporting earnings beats, lifting shares 20.4% as investors react to stronger-than-expected quarterly results and improved outlook.
Want a deeper read on THC?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Tenet Healthcare (THC) is a Top-Ranked Momentum Stock: Should You Buy?
zacks.com · Nov 19
Tenet Healthcare Corporation (THC) is Attracting Investor Attention: Here is What You Should Know
zacks.com · Nov 19
Here's Why Tenet Healthcare (THC) is a Strong Value Stock
zacks.com · Nov 16
Brown Advisory Large-Cap Sustainable Value Strategy Q3 2026 Portfolio Review
seekingalpha.com · Nov 13
Here's Why Tenet Healthcare (THC) is a Strong Growth Stock
zacks.com · Nov 6
Hospital Stocks Soared as Democrats Took Congress
247wallst.com · Nov 5
Healthcare Stocks Bounce on Midterm Results. A Bull Market Case Is Developing.
barrons.com · Nov 4
Tenet Healthcare Corporation (THC) Is a Trending Stock: Facts to Know Before Betting on It
zacks.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 20, 2026 · Live quote · Not investment advice